WallStSmart

DaVita HealthCare Partners Inc (DVA)vsNutex Health Inc (NUTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DaVita HealthCare Partners Inc generates 1472% more annual revenue ($13.84B vs $879.95M). NUTX leads profitability with a 11.0% profit margin vs 5.7%. NUTX trades at a lower P/E of 9.9x. DVA earns a higher WallStSmart Score of 70/100 (B-).

DVA

Strong Buy

70

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 5.3Quality: 5.5
Piotroski: 3/9Altman Z: 1.22

NUTX

Buy

64

out of 100

Grade: C+

Growth: 8.0Profit: 9.0Value: 8.3Quality: 7.0
Piotroski: 4/9Altman Z: 2.49
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DVASignificantly Overvalued (-17.0%)

Margin of Safety

-17.0%

Fair Value

$123.34

Current Price

$192.16

$68.82 premium

UndervaluedFair: $123.34Overvalued
NUTXUndervalued (+63.6%)

Margin of Safety

+63.6%

Fair Value

$283.22

Current Price

$135.10

$148.12 discount

UndervaluedFair: $283.22Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DVA4 strengths · Avg: 9.0/10
Return on EquityProfitability
81.0%10/10

Every $100 of equity generates 81 in profit

Debt/EquityHealth
-17.5010/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.658/10

Growing faster than its price suggests

EPS GrowthGrowth
43.5%8/10

Earnings expanding 43.5% YoY

NUTX5 strengths · Avg: 9.4/10
P/E RatioValuation
9.9x10/10

Attractively priced relative to earnings

Operating MarginProfitability
37.5%10/10

Strong operational efficiency at 37.5%

EPS GrowthGrowth
95.9%10/10

Earnings expanding 95.9% YoY

Return on EquityProfitability
27.8%9/10

Every $100 of equity generates 28 in profit

Price/BookValuation
2.7x8/10

Reasonable price relative to book value

Areas to Watch

DVA3 concerns · Avg: 2.7/10
Profit MarginProfitability
5.7%3/10

5.7% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

NUTX3 concerns · Avg: 3.3/10
Revenue GrowthGrowth
2.2%4/10

2.2% revenue growth

Market CapQuality
$927.61M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.013/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : DVA

The strongest argument for DVA centers on Return on Equity, Debt/Equity, PEG Ratio. PEG of 0.65 suggests the stock is reasonably priced for its growth.

Bull Case : NUTX

The strongest argument for NUTX centers on P/E Ratio, Operating Margin, EPS Growth.

Bear Case : DVA

The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.

Bear Case : NUTX

The primary concerns for NUTX are Revenue Growth, Market Cap, Debt/Equity.

Key Dynamics to Monitor

NUTX carries more volatility with a beta of 2.06 — expect wider price swings.

DVA is growing revenue faster at 6.0% — sustainability is the question.

DVA generates stronger free cash flow (219M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

DVA scores higher overall (70/100 vs 64/100). NUTX offers better value entry with a 63.6% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DaVita HealthCare Partners Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.

Nutex Health Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Nutex Health, Inc. is a technology-based healthcare services company. The company is headquartered in Houston, Texas.

Want to dig deeper into these stocks?